Adar1 Capital Management, Llc Acquires 50,000 Shares of Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $700,000.00. Following the purchase, the insider directly owned 829,784 shares in the company, valued at $11,616,976. This trade represents a 6.41% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 12th, Adar1 Capital Management, Llc acquired 800 shares of Rallybio stock. The stock was bought at an average cost of $13.83 per share, with a total value of $11,064.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was bought at an average price of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were bought at an average cost of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Stock Performance

Rallybio stock opened at $14.21 on Friday. The company has a market capitalization of $75.17 million, a PE ratio of -5.55 and a beta of -1.10. The company has a 50 day moving average price of $9.77 and a 200-day moving average price of $6.99. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $15.31.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 54.44% and a negative net margin of 911.07%.The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million.

Institutional Trading of Rallybio

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd raised its stake in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its stake in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares in the last quarter. Geode Capital Management LLC grew its holdings in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. 90.34% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RLYB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rallybio has a consensus rating of “Sell”.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.